

## EDITORIAL • RÉDACTION

### Editor • Rédacteur

John Hoey (john.hoey@cma.ca)

**Senior Deputy Editor • Rédactrice adjointe principale**  
Anne Marie Todkill (annemarie.todkill@cma.ca)

**Deputy Editor (Scientific) • Rédactrice adjointe, Sciences**  
Jennifer Thomas (jennifer.thomas@cma.ca)

### Associate Editors • Rédacteurs associés

Tom Elmslie (telmslie@scohs.on.ca)

Ken Flegel (ken.flegel@muhc.mcgill.ca)

Anita Palepu (anita@hivnet.ubc.ca)

Erica Weir (erica.weir@utoronto.ca)

Eric Wooltorton (ewooltorton@yahoo.com)

Nick Barrowman (Biostatistics • Biostatistique)

### Editorial Fellow • Boursier en rédaction médicale

James Maskalyk (james.maskalyk@cma.ca)

### Ombudsman-Ethicist • Ombudsman-éthicien

John Dossetor (ombudsman@cma.ca)

### Managing Editor • Rédacteur administratif

Randy Chafy (randy.chafy@cma.ca)

### News Editor

### Rédacteur, informations générales

Patrick Sullivan (patrick.sullivan@cma.ca)

### Editors • Rédacteurs

Patricia Lightfoot (patricia.lightfoot@cma.ca)

Jennifer Raiche (jennifer.raiche@cma.ca)

Kate Schissler (kate.schissler@cma.ca)

Barbara Sibbald (barbara.sibbald@cma.ca)

Steven Wharry (steve.wharry@cma.ca)

### Editorial Administrator • Administratrice de rédaction

Carole Corkery (carole.corkery@cma.ca)

### Editorial Assistants • Assistantes à la rédaction

Erin Archibald (erin.archibald@cma.ca)

Wilma Fatica (wilma.fatica@cma.ca)

Melanie Mooy (melanie.mooy@cma.ca)

Joyce Quintal (joyce.quintal@cma.ca)

### Translation Coordinator

### Coordonnatrice de la traduction

Marie Saumure

### Contributing Editors • Rédactrices invitées

Gloria Baker; Charlotte Gray; Peggy Robinson;

Lori Anderson; Ann Bolster

### Editorial Board • Conseil de rédaction

Paul W. Armstrong (Edmonton)

Neil R. Cashman (Toronto)

Deborah J. Cook (Hamilton)

David H. Feeny (Edmonton)

William Ghali (Calgary)

Frank R. de Grijijl (Utrecht, the Netherlands)

Judith G. Hall (Vancouver)

Carol P. Herbert (London)

Neill Iscoe (Toronto)

Alejandro R. Jadad (Toronto)

Jerome P. Kassirer (Boston)

Finlay A. McAlister (Edmonton)

Allison J. McGeer (Toronto)

Harriet L. MacMillan (Hamilton)

David Moher (Ottawa)

Susan Phillips (Kingston)

André Picard (Montreal)

Donald A. Redelmeier (Toronto)

Martin T. Schechter (Vancouver)

Sander J.O. Veldhuyzen van Zanten (Halifax)

Salim Yusuf (Hamilton)

All editorial matter in *CMAJ* represents the opinions of the authors and not necessarily those of the Canadian Medical Association (CMA). The CMA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CMAJ* including editorials, studies, reports, letters and advertisements.

Tous les articles à caractère éditorial dans le *JAMC* représentent les opinions de leurs auteurs et n'engagent pas l'Association médicale canadienne (AMC). L'AMC décline toute responsabilité civile ou autre quant à toute erreur ou omission ou à l'usage de tout conseil ou information figurant dans le *JAMC* et les éditoriaux, études, rapports, lettres et publicités y paraissant.

## One conclusion may hide another

The American poet Kenneth Koch is perhaps most famous for his poem "One Train May Hide Another."<sup>1</sup> Noticing, as he crossed a railway track, the warning sign that became the title of the poem, he reflected on similar circumstances. For example, "In a poem one line may hide another line ... And so when you read, wait until you have read the next line — Then it is safe to go on reading." The same may be true of research.

Koch died at age 77 in the same week that the Women's Health Initiative study of hormone replacement therapy was stopped because of excessive risks of invasive breast cancer.<sup>2</sup> Within the first year of the trial, which involved 16 608 postmenopausal women up to age 79 years, participants who had been randomly assigned to receive a combination of conjugated equine estrogen and medroxyprogesterone acetate (Prempro, Wyeth Ayerst) experienced higher rates of coronary artery disease and pulmonary embolism than participants receiving a placebo (see pages 377 and 387). Later the women receiving the active drug experienced higher rates of stroke and breast cancer. Hip fracture and colorectal cancer rates were lower than in the placebo group. The trial was stopped when the increases in the risk for breast cancer and in all risks combined exceeded predetermined boundaries.

Hormone replacement therapy became popular in 1968 with the publication of a best-selling book by Robert Wilson, *Feminine Forever*,<sup>3</sup> and its subsequent promotion by the author and his wife. Wilson believed that "the menopause is both unnecessary and harmful" and in "the incontrovertible fact that the deficiency disease created by ovarian decline with its painful, disabling and even fatal consequences, is responsive to therapy [author's italics]."<sup>4</sup> As reported by Kolata and Peterson,<sup>5</sup> Wilson's book and lecture tours were paid for by Wyeth Ayerst.

On the basis of observational (non-randomized) studies, estrogen was believed to reduce the risk of heart disease

and osteoporotic fractures in postmenopausal women. The science seemed so convincing that an advisory committee of the US Food and Drug Administration (FDA) recommended that randomized controlled trials were not necessary and that estrogen could be marketed as being protective against heart disease. The FDA, under pressure from the National Women's Health Network, overruled its advisors and insisted that hormone replacement therapy be subjected to a randomized trial. Perhaps, as Koch put it, the FDA suspected that "[I]n the laboratory, one invention may hide another invention."<sup>1</sup>

The Women's Health Initiative study serves to remind us that we should wait for the first train to pass. In this issue, David Sackett, long a student and passionate advocate of randomized trials, Anna Day, a leader in the reform of the women's health and research agenda, and Salim Yusuf and Sonia Anand comment on the study (see pages 357, 361 and 363); Yusuf is a member of the data and safety monitoring board for the study. As Sackett points out, it is of no value to simply blame the drug manufacturers for unscrupulous behaviour. By trying to increase market share and profits for their shareholders, they are behaving as a model industry. Perhaps we, the physicians who prescribed the drugs (and maybe even the patients who requested them) are at fault: Why did we accept evidence from nonrandomized studies so readily?

### References

1. Koch K. *One train*. New York: Alfred A. Knopf; 1994.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288(3):321-33.
3. Wilson RA. *Feminine forever*. New York: M. Evans and Company, Inc.; 1968.
4. Wilson RA, Marino ER, Wilson TA. Norethynodrel-mestranol (novid) for prevention and treatment of the climacteric. *J Am Geriatr Soc* 1966; 14(10):967-85.
5. Kolata G, Petersen M. Hormone replacement study a shock to the medical system. *New York Times* 2002 Jul 10.